GLP2 versus insulin glargine in type 2 diabetes and increased cardiovascular risk (SURPASS-4): A randomised, open-label, parallel-group, multicentre, phase 3 trial
FlintARabenAAstrupAHolstJJGlucagon-likepeptide 1 promotes satiety and suppresses energy intake in humans
MicroRNA-194: a novel regulator of glucagon-like peptide-1 synthesis in intestinal L cells
Una vez que la gente se dio cuenta de los beneficios de estos medicamentos para la prdida de peso, su demanda aument
[1] [6] Whilst these reductions are modest, they are clinically meaningful when considered alongside the medication's other cardiovascular benefits
In this context, the aim of the present document is to summarize, in the form of a narrative literature review, the currently available data on the main mechanisms of action of GIP/GLP-1 co-agonists and the clinical effects of tirzepatide evaluated in various clinical trials